Effects of some anti-diabetic and cardioprotective agents on proliferation and apoptosis of human coronary artery endothelial cells

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Eriksson, Linnéa ^a   Erdogdu, Özlem ^a   Nyström, Thomas ^a   Zhang, Qimin ^a   Sjöholm, Åke ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

At1 receptor antagonist; Coronary artery disease; Diabetes; Endothelium; Insulin; Lipids; Metformin; Peroxisome proliferator activated receptor gamma agonist; Statin

Indexed keywords

BLX 1002; C PEPTIDE; CANDESARTAN; CASPASE 3; GLIMEPIRIDE; GLUCOSE; INSULIN LISPRO; METFORMIN; PALMITIC ACID; PIOGLITAZONE; ROSUVASTATIN; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; BENZIMIDAZOLE DERIVATIVE; CARDIOTONIC AGENT; FLUOROBENZENE; INSULIN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TETRAZOLE DERIVATIVE;

ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CELL VIABILITY; DNA FRAGMENTATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN CORONARY ARTERY ENDOTHELIAL CELL; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; CELL CULTURE; CELL SURVIVAL; CORONARY BLOOD VESSEL; CYTOLOGY; VASCULAR ENDOTHELIUM;

APOPTOSIS; BENZIMIDAZOLES; CARDIOTONIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PYRIMIDINES; SULFONAMIDES; TETRAZOLES; THIAZOLIDINEDIONES;

EID: 84862806557     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-27     Document Type: Article

References (45)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(1):4-14. 10.1016/j.diabres.2009.10.007, 19896746.
2. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006, 22(1):4-10. 10.1002/dmrr.568, 15991254.
3. Sjoholm A, Nystrom T. Endothelial inflammation in insulin resistance. Lancet 2005, 365(9459):610-612.
4. Dandona P, Ghanim H, Chaudhuri A, Mohanty P. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. J Diabetes Complications 2008, 22(1):62-75. 10.1016/j.jdiacomp.2006.10.009, 18191079.
5. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22(1):36-52. 10.1210/er.22.1.36, 11159815.
6. Avogaro A, de Kreutzenberg SV, Fadini G. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 2008, 82(Suppl 2):S94-S101.
7. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007, 3(1):46-56. 10.1038/ncpendmet0366, 17179929.
8. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97(11):2601-2610. 10.1172/JCI118709, 507347, 8647954.
9. Nathanson D, Nystrom T. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium. Mol Cell Endocrinol 2009, 297(1-2):112-126. 10.1016/j.mce.2008.11.016, 19038307.
10. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res 2002, 90(1):107-111. 10.1161/hh0102.102359, 11786526.
11. Lundman P, Tornvall P, Nilsson L, Pernow J. A triglyceride-rich fat emulsion and free fatty acids but not very low density lipoproteins impair endothelium-dependent vasorelaxation. Atherosclerosis 2001, 159(1):35-41. 10.1016/S0021-9150(01)00478-6, 11689204.
12. Ho FM, Liu SH, Liau CS, Huang PJ, Lin-Shiau SY. High glucose-induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000, 101(22):2618-2624.
13. Chai W, Liu Z. p38 mitogen-activated protein kinase mediates palmitate-induced apoptosis but not inhibitor of nuclear factor-kappaB degradation in human coronary artery endothelial cells. Endocrinology 2007, 148(4):1622-1628.
14. Cifarelli V, Geng X, Styche A, Lakomy R, Trucco M, Luppi P. C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. Diabetologia 2011, 54(10):2702-2712. 10.1007/s00125-011-2251-0, 21773684.
15. Hamaguchi T, Hirose T, Asakawa H, Itoh Y, Kamado K, Tokunaga K, Tomita K, Masuda H, Watanabe N, Namba M. Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide. Diabetes Res Clin Pract 2004, 66(Suppl 1):S129-S132.
16. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001, 121:13-18.
17. Matsumoto N, Manabe H, Ochiai J, Fujita N, Takagi T, Uemura M, Naito Y, Yoshida N, Oka S, Yoshikawa T. An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity. Shock 2003, 19(6):547-552. 10.1097/01.shk.0000070734.34700.80, 12785010.
18. Li X, Yang G, Zhao G, Wu B, Edin ML, Zeldin DC, Wang DW. Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertens Res 2011, 34(7):869-875. 10.1038/hr.2011.44, 21562509.
19. Brunmair B, Staniek K, Lehner Z, Dey D, Bolten CW, Stadlbauer K, Luger A, Furnsinn C. Lipophilicity as a determinant of thiazolidinedione action in vitro: findings from BLX-1002, a novel compound without affinity to PPARs. Am J Physiol Cell Physiol 2011, 300(6):C1386-C1392. 10.1152/ajpcell.00401.2010, 21346152.
20. Zhang F, Dey D, Branstrom R, Forsberg L, Lu M, Zhang Q, Sjoholm A. BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Physiol Cell Physiol 2009, 296(2):C346-C354.
21. Brunmair B, Staniek K, Gras F, Scharf N, Althaym A, Clara R, Roden M, Gnaiger E, Nohl H, Waldhausl W, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 2004, 53(4):1052-1059. 10.2337/diabetes.53.4.1052, 15047621.
22. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2009, 325(1-2):26-35.
23. Edwards SJ, Reader KL, Lun S, Western A, Lawrence S, McNatty KP, Juengel JL. The cooperative effect of growth and differentiation factor-9 and bone morphogenetic protein (BMP)-15 on granulosa cell function is modulated primarily through BMP receptor II. Endocrinology 2008, 149(3):1026-1030.
24. Sjoholm A, Zhang Q, Welsh N, Hansson A, Larsson O, Tally M, Berggren PO. Rapid Ca2+ influx and diacylglycerol synthesis in growth hormone-mediated islet beta -cell mitogenesis. J Biol Chem 2000, 275(28):21033-21040. 10.1074/jbc.M001212200, 10748000.
25. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376(6535):37-43. 10.1038/376037a0, 7596430.
26. Kageyama S, Yokoo H, Tomita K, Kageyama-Yahara N, Uchimido R, Matsuda N, Yamamoto S, Hattori Y. High glucose-induced apoptosis in human coronary artery endothelial cells involves up-regulation of death receptors. Cardiovasc Diabetol 2011, 10:73. 10.1186/1475-2840-10-73, 3161855, 21816064.
27. Serizawa K, Yogo K, Aizawa K, Tashiro Y, Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc Diabetol 2011, 10:105. 10.1186/1475-2840-10-105, 3248842, 22107602.
28. Varma S, Lal BK, Zheng R, Breslin JW, Saito S, Pappas PJ, Hobson RW, Duran WN. Hyperglycemia alters PI3k and Akt signaling and leads to endothelial cell proliferative dysfunction. Am J Physiol Heart Circ Physiol 2005, 289(4):H1744-H1751. 10.1152/ajpheart.01088.2004, 1618822, 15964918.
29. McGinn S, Saad S, Poronnik P, Pollock CA. High glucose-mediated effects on endothelial cell proliferation occur via p38 MAP kinase. Am J Physiol Endocrinol Metab 2003, 285(4):E708-E717.
30. Berk BC, Abe JI, Min W, Surapisitchat J, Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. Ann N Y Acad Sci 2001, 947:93-109. discussion 109-111.
31. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115(18):2435-2441. 10.1161/CIRCULATIONAHA.107.693739, 17438147.
32. Nickson CM, Doherty PJ, Williams RL. Novel polymeric coatings with the potential to control in-stent restenosis-an in vitro study. J Biomater Appl 2010, 24(5):437-452. 10.1177/0885328208099338, 19033327.
33. Gousseva N, Kugathasan K, Chesterman CN, Khachigian LM. Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J Cell Biochem 2001, 81(3):523-534. 10.1002/1097-4644(20010601)81:3<523::AID-JCB1066>3.0.CO;2-E, 11255235.
34. Enomoto S, Sata M, Fukuda D, Nakamura K, Nagai R. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice. Biomed Pharmacother 2009, 63(1):19-26. 10.1016/j.biopha.2007.11.002, 18162361.
35. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7(8):606-619. 10.1038/nrg1879, 16847462.
36. Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000, 101(13):1539-1545.
37. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006, 55(2):496-505. 10.2337/diabetes.55.02.06.db05-1064, 16443786.
38. Piro S, Spampinato D, Spadaro L, Oliveri CE, Purrello F, Rabuazzo AM. Direct apoptotic effects of free fatty acids on human endothelial cells. Nutr Metab Cardiovasc Dis 2008, 18(2):96-104. 10.1016/j.numecd.2007.01.009, 17560770.
39. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20(2):402-409. 10.1161/01.ATV.20.2.402, 10669636.
40. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88(4):435-437. 10.1016/S0092-8674(00)81883-8, 9038334.
41. Kim JE, Kim YW, Lee IK, Kim JY, Kang YJ, Park SY. AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci 2008, 106(3):394-403. 10.1254/jphs.FP0071857, 18360094.
42. Artwohl M, Holzenbein T, Furnsinn C, Freudenthaler A, Huttary N, Waldhausl WK, Baumgartner-Parzer SM. Thiazolidinediones inhibit apoptosis and heat shock protein 60 expression in human vascular endothelial cells. Thromb Haemost 2005, 93(5):810-815.
43. Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M, Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 2007, 192(1):67-74. 10.1016/j.atherosclerosis.2006.06.026, 16876172.
44. Fujisawa K, Nishikawa T, Kukidome D, Imoto K, Yamashiro T, Motoshima H, Matsumura T, Araki E. TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun 2009, 379(1):43-48. 10.1016/j.bbrc.2008.11.141, 19084501.
45. Chen J, Li D, Zhang X, Mehta JL. Tumor necrosis factor-alpha-induced apoptosis of human coronary artery endothelial cells: modulation by the peroxisome proliferator-activated receptor-gamma ligand pioglitazone. J Cardiovasc Pharmacol Ther 2004, 9(1):35-41. 10.1177/107424840400900i106, 15094967.